MS News Briefs

Increased Risk of Cardiac Events Identified in Patients With Multiple Sclerosis

Findings from a systematic review and meta-analysis revealed an increased risk of myocardial infarction and heart failure in patients with multiple sclerosis (MS). The study was published in Multiple Sclerosis and Related Disorders. Subgroup analysis revealed that the risk of heart disease was more predominant in women and younger individuals with MS. Women with MS…

Seven-Domain Framework Finds Poor Sleep Health in Many MS Patients

Results from a study examining sleep health in individuals with multiple sclerosis (MS) demonstrated that 76% of participants measured in extreme ranges for at least 2 of 7 sleep domains. Poor sleep quality affected 45% of participants, abnormal sleep timing affected 35%, and pathological daytime sleepiness affected 33%. Investigators calculated median values of 456.3 minutes…

Durhane Wong-Rieger

Dr. Durhane Wong-Rieger on the Challenges Faced by Rare Disease Patients in Canada

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Durhane Wong-Rieger, PhD, president and CEO of the Canadian Organization for Rare Disorders (CORD) and chair of Rare Diseases International (RDI). Dr. Wong-Rieger talks about the challenges of diagnosing and treating diseases in Canada, as well as advancing access to therapies around the globe. Read the…

Multiple Sclerosis Diagnosis

New Partnership Could Improve MS Diagnosis and Progression Monitoring

Innodem Neurosciences and Novartis Pharmaceuticals Canada Inc. signed a multiyear partnership to conduct a clinical trial that could help clinicians better diagnose and monitor the progression of multiple sclerosis (MS). Novartis will fund the cross-sectional and longitudinal trial to validate Innodem’s artificial intelligence-powered, patented, eye-tracking software technology in assisting clinicians in diagnosing and monitoring disease…

MS lesions

Curcumin Lacked Value When Added to Treatment Regimen in Relapsing MS Patients

Curcumin supplementation is safe and tolerated well by patients with relapsing multiple sclerosis (MS) receiving treatment with subcutaneous interferon (IFN) β-1a, according to a new study published in Multiple Sclerosis and Related Disorders. However, this add-on therapy did not improve the clinical efficacy of the regimen. The authors did not observe any statistically significant difference…

Restless Legs Syndrome More Prevalent in Patients With Multiple Sclerosis

The prevalence of restless legs syndrome is much higher in people with multiple sclerosis (MS) than in healthy controls, according to a systematic review and meta-analysis of the literature. “Our updated systematic review strengthens the evidence of the increased risk of [restless legs syndrome] amongst [people with MS],” wrote the authors of the study, which…

types of ms

New MRI Technique Monitors Oxygen Metabolism in Active MS Lesions

The combination of oxygen extraction fraction (OEF) and neural tissue susceptibility (𝛘n) brain mapping can be used to quantify the metabolic activity of active multiple sclerosis (MS) brain lesions, according to a new article published in the Journal of Cerebral Blood Flow & Metabolism. The study found that lesion rims had higher OEF and 𝛘n…

Multiple Sclerosis Therapies

MS Treatment Reduces Efficacy of SARS-CoV-2 Vaccine

Multiple sclerosis (MS) patients who received anti-CD20 treatment (ocrelizumab) prior to receiving both doses of SARS-CoV-2 vaccines had a significantly reduced response to the vaccinations, according to a recent study published in Multiple Sclerosis and Related Disorders. After 2 vaccine doses, just 36.7% of the patients in the study had detectable levels of SARS-CoV-2-specific immunoglobulin-G…

Targeting Epstein-Barr Virus Could Reduce Its Effect on Multiple Sclerosis

The Epstein-Barr virus (EBV) transcription factor Epstein-Barr Nuclear Antigen 2 (EBNA2) can regulate gene expression depending on multiple sclerosis (MS) risk alleles, likely promoting viral infection, a new study in Australia found. “This is consistent with the concept that these MS risk loci affect MS risk through altering the response to EBNA2,” the researchers wrote.…

Next post in MS News Briefs